RecruitingPhase 4NCT04657822
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Studying Genetic hemoglobinopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- Crizanlizumab(drug)
- Enrollment
- 130 enrolled
- Eligibility
- 100 years · All sexes
- Timeline
- 2021 – 2031
Study locations (28)
- University Of Alabama, Birmingham, Alabama, United States
- Childrens National Hospital, Washington D.C., District of Columbia, United States
- Augusta University Georgia, Augusta, Georgia, United States
- East Carolina University, Greenville, North Carolina, United States
- Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Cook Childrens Medical Center, Fort Worth, Texas, United States
- Novartis Investigative Site, Brussels, Belgium
- Novartis Investigative Site, Laken, Belgium
- Novartis Investigative Site, Liège, Belgium
- Novartis Investigative Site, Salvador, Estado de Bahia, Brazil
- Novartis Investigative Site, Ribeirão Preto, São Paulo, Brazil
- Novartis Investigative Site, São Paulo, São Paulo, Brazil
- Novartis Investigative Site, Valledupar, Cesar Department, Colombia
- Novartis Investigative Site, Cali, Valle del Cauca Department, Colombia
- Novartis Investigative Site, Montería, Colombia
- +13 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04657822 on ClinicalTrials.govOther trials for Genetic hemoglobinopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07488091Multi Disciplinary Sickle Cell Disease Obstetrics Care Program in GhanaUniversity of Ghana Medical School
- RECRUITINGNANCT07316478Stress Management and Mindfulness Intervention for Patients With Sickle Cell DiseaseUniversity of Pennsylvania
- RECRUITINGNANCT07188766Efficacy of Liberal Versus Restricted IV Fluid Approach in the Management of Sickle Cell Vaso-Occlusive CrisisImam Abdulrahman Bin Faisal University
- RECRUITINGNANCT07090668Trans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell DiseaseEmory University
- RECRUITINGPHASE1NCT07087262A Phase I Study of SNH-119014 in Healthy VolunteersScinnoHub Pharmaceutical Co., Ltd.
- RECRUITINGNANCT06886477Sickle Cell, Pain and Mediterranean DietUniversity of Illinois at Chicago
- RECRUITINGNANCT06367192School Readiness Intervention for Preschool Children With Sickle Cell DiseaseSt. Jude Children's Research Hospital
- RECRUITINGNANCT06735625Pilot Study "AHSP as a Biomarker of Sickle Cell Disease in a Population of Adults and Children"Centre Hospitalier de Saint-Denis